Indication assessment · §3
Primary mitochondrial myopathy and bioenergetic disorders — trial records
Trial records in the Institute's register bearing on primary mitochondrial myopathy and bioenergetic disorders.
§3Trials in this indication
9 trial records in the Institute's register bear on this indication, of which 2 are published trials.
Table 2. Trial records bearing on primary mitochondrial myopathy and bioenergetic disorders.
| Record | Compound | Phase | Design | Randomised | Year |
|---|---|---|---|---|---|
| MMPOWER-2 | SS-31 (elamipretide) | Phase 2 | Randomised crossover | 30 | 2018 |
| MMPOWER-3 | SS-31 (elamipretide) | Phase 3 | Randomised, double-blind, placebo-controlled | 218 | 2022 |
| MMPOWER-2-ELDERLYprogramme record | SS-31 (elamipretide) | Phase 2 | Randomised, double-blind, placebo-controlled | — | 2018 |
| MMPOWER-3-OLEprogramme record | SS-31 (elamipretide) | Phase 3 | Single-arm open-label | — | 2022 |
| MMPOWER-2-OLEprogramme record | SS-31 (elamipretide) | Phase 2 | Single-arm open-label | — | 2018 |
| MMPOWER-2-ADHERENCEprogramme record | SS-31 (elamipretide) | Phase 2 | Observational | — | 2018 |
| MMPOWER-3-BIOMARKERprogramme record | SS-31 (elamipretide) | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2022 |
| MMPOWER-2-BIOMARKERprogramme record | SS-31 (elamipretide) | Phase 2 | Randomised, double-blind, placebo-controlled | — | 2018 |
| MMPOWER-3-ADHERENCEprogramme record | SS-31 (elamipretide) | Phase 3 | Observational | — | 2022 |
| This facet in the trial register. | |||||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology 2014;171(8):2029–2050. doi:10.1111/bph.12461 · PMID 24117165
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.
Compound Evidence Institute · CEI-IN-31/3 · https://compoundevidence.com/indications/mitochondrial/trials/ · retrieved 30 July 2026